GlaxoSmithKline Statistics
Want to see GSK full AI Analyst Report?
GlaxoSmithKline (GSK) Stock Statistics & Valuation Metrics
Total Valuation
GlaxoSmithKline has a market cap or net worth of $97.86B. The enterprise value is $125.13B.
- Market Cap
- $97.86B
- Enterprise Value
- $125.13B
Share Statistics
GlaxoSmithKline has 2,022,719,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 2,022,719,600
- Owned by Insiders
- ―
- Owned by Institutions
- 14.12%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 15.80%.
- Return on Equity (ROE)
- 0.35
- Return on Assets (ROA)
- 0.09
- Return on Invested Capital (ROIC)
- 15.80%
- Return on Capital Employed (ROCE)
- 0.20
- Revenue Per Employee
- 488.73K
- Profits Per Employee
- 85.52K
- Employee Count
- 66,841
- Asset Turnover
- 0.54
- Inventory Turnover
- 1.52
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 17.20. GlaxoSmithKline’s PEG ratio is -0.84.
- PE Ratio
- 17.20
- PS Ratio
- 2.22
- PB Ratio
- 3.97
- Price to FCF
- 10.89
- Price to Operating Cash Flow
- 8.71
- PEG Ratio
- -0.84
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 2.82.
- Revenue
- 32.67B
- Gross Profit
- 23.65B
- Operating Income
- 7.93B
- Pretax Income
- 7.40B
- Net Income
- 5.72B
- EBITDA
- 10.37B
- Earnings Per Share (EPS)
- 2.82
Cash Flow
In the last 12 months, operating cash flow was 8.50B and capital expenditures -1.70B, giving a free cash flow of 6.79B billion.
- Operating Cash Flow
- 8.50B
- Free Cash Flow
- 6.79B
- Free Cash Flow per Share
- 3.41
Dividends & Yields
GlaxoSmithKline pays an annual dividend of $0.45, resulting in a dividend yield of 3.78%
- Dividend Per Share
- $0.45
- Dividend Yield
- 3.78%
- Payout Ratio
- 38.65%
- Free Cash Flow Yield
- 9.18%
- Earnings Yield
- 5.84%
Stock Price Statistics
- Beta
- 0.24
- 52-Week Price Change
- 2.55%
- 50-Day Moving Average
- 48.89
- 200-Day Moving Average
- 51.35
- Relative Strength Index (RSI)
- 44.48
- Average Volume (3m)
- 4.03M
Important Dates
GlaxoSmithKline upcoming earnings date is Feb 03, 2027, Before Open (Not Confirmed).
- Last Earnings Date
- Oct 28, 2026
- Next Earnings Date
- Feb 03, 2027
- Ex-Dividend Date
- May 15, 2026
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 108.20%
- Current Ratio
- 0.82
- Quick Ratio
- 0.54
- Debt to Market Cap
- 0.24
- Net Debt to EBITDA
- 1.38
- Interest Coverage Ratio
- 12.05
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
- Income Tax
- 1.11B
- Effective Tax Rate
- 0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 8.95, with an EV/FCF ratio of 13.93.
- EV to Sales
- 2.84
- EV to EBITDA
- 8.95
- EV to Free Cash Flow
- 13.93
- EV to Operating Cash Flow
- 11.13
Balance Sheet
GlaxoSmithKline has $2.98B in cash and marketable securities with $23.86B in debt, giving a net cash position of -$20.88B billion.
- Cash & Marketable Securities
- $2.98B
- Total Debt
- $23.86B
- Net Cash
- -$20.88B
- Net Cash Per Share
- -$10.32
- Tangible Book Value Per Share
- -$7.55
Margins
Gross margin is 73.52%, with operating margin of 23.80%, and net profit margin of 12.97%.
- Gross Margin
- 73.52%
- Operating Margin
- 23.80%
- Pretax Margin
- 16.05%
- Net Profit Margin
- 12.97%
- EBITDA Margin
- 31.72%
- EBIT Margin
- 25.11%
Analyst Forecast
The average price target for GlaxoSmithKline is $57.95, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $57.95
- Price Target Upside
- 19.29% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- 6.93%
- EPS Growth Forecast
- -18.14%
Scores
- Smart Score
- 6
- AI Score
- 67

